A newly-developed drug is expected to cure the type 1 diabetes

"Efficacy of a single injection can maintain at least four months." An US research team has developed a new drug to control blood sugar and gained success in animal experiments. The researchers say their study involves a hormone which naturally exists in the human brain, and it is expected to provide assistance for the treatment of diabetes in the future. Related papers were published online at the website of journal Nature.

Type 2 diabetes is the most common disease worldwide, and its incidence is increasing year by year. Its characterization is that the blood sugar would pathologically elevate. If left unchecked and uncontrolled, it can easily lead to serious complications and even be life-threatening.

Previous research had found that injecting a hormone which involved in many biological processes - fibroblast growth factor 1 (FGF1) into the peripheral blood system of mice can produce a strong anti-diabetic effect. But to achieve this, a large amount of drug is needed and the injection times should be more often.

In the new study, Mike Schwartz and his team at University of Washington changed an throught, trying to directly inject the hormone into the brain of mice and rat with type 2 diabetes. It was found that only one injection of FGF1 can make blood glucose levels in these animals maintain normal for at least four months.

The researchers say that this treatment works on obese mice caused diet and genetical factor. In addition, for genetically-induced obese rats, the therapy also proved to be effective. This long-lasting anti-diabetic effect did not influnced by food intake or body weight, indicating that the improvement of blood sugar levels has nothing to do with weight loss. The study fully demonstrated that brain can play a strong role in systemic glucose signaling.

Schwartz said that although the therapy is currently effective only on mild diabetic rodents, the finding has the potential to be converted to clinical drug for diabetes because it involves a hormone which naturally exists in humnan brain. However, because the specific mechanism of the therapy is not yet clear, they also need further research to answer this question and determine whether FGF1 have side effects.

See more: http://www.cusabio.com/ELISA-Kit/Dog-complement-fragment-3aC3a-ELISA-kit-1042166.html

Better understanding of how some drugs affecting cognitive impairment and dementia

According to a new study published in JAMA Neurology, many over-the-counter drugs contain anticholinergic drug, such as nighttime cold medicine, and the occurrence of anticholinergic drugs and cognitive dysfunction related to the elderly.

Previous studies have found that anti-cholinergic drugs can increase the body's cognitive impairment and dementia risk. The study included a total of 451 cognitively normal older (average age 73.3 years), these subjects from the US National Research Program: Alzheimer's disease and neuroimaging studies Indiana memory and aging research. In which 60 (13%) subjects taking at least one of the high activity of anticholinergic drugs. By analyzing brain scans, the researchers explored the potential mechanisms associated with both.

Cognition and memory tests showed that compared with patients not taking anticholinergic drugs, patients taking these drugs lower short-term memory and executive function test, the average score. Taking anticholinergic drugs in patients Wechsler Memory Scale revised logical memory immediate recall test average score was significantly lower than patients not taking anticholinergic drugs for their executive function composite score as well.

Results positron emission tomography (PET) showed that patients taking anticholinergic drugs reduce their glucose metabolism, glucose metabolism is a biomarker of brain activity. Regional activity in the hippocampus and memory-related also reduced, previous studies have confirmed that this was an early manifestation of Alzheimer's disease occur.

Magnetic resonance imaging (MRI) showed great correlation between brain structure and use of anticholinergic drugs. Compared with patients not taking anticholinergic drugs, patients taking anticholinergic drugs full leather smaller, but larger and ventricle.

"These findings led us to a better understanding of how these drugs affect brain which increases the risk of body's cognitive impairment and dementia," the study's lead researcher, chief researcher, from Indianapolis, Indiana University Health Sciences Center shannon Risacher said, "based on these findings, for elderly patients, doctors should start to think about alternative medicine anticholinergic drugs."

Read more: http://www.cusabio.com/ELISA-Kit/Guinea-pig-dopamineDA-ELISA-kit-1035515.html

Newly-developed drug may be possible to cure tick disease

Japanese researchers recently announced that animal experiments have shown the drug Favipiravir is effective for the treatment of severe fever with thrombocytopenia syndrome which takes ticks as infection vectors. Since it has gone through security check as influenza drugs, Favipiravir is expected to be used to treat this "Tick disease" soon.

Severe fever with thrombocytopenia syndrome, commonly known as "tick disease", is an acute infectious disease caused by a new kind of Bunia virus and this virus takes ticks for the infection vectors. In western Japan, there are 170 cases being reported in the past three years, including 46 deaths. There are no effective therapeutic drugs and vaccines at present.

Researchers at National Institute of Infectious Diseases in Japan say they made the laboratory mice infected with the relevant virus, and then let them take Favipiravir within five days. Comparing the mice above with mice without treatment and mice taking antiviral drugs Ribavirin, the researchers found that mice without treatment almost all died; about 40% of the mice taking ribavirin died; while mice taking Favipiravir all survived.

In another experiment, the research team postponed Favipiravir to the mice infected with virus. The findings showed that, the mice all survived even the drugs were taken on the third day of infection; there are still about half of the mice survived when the drugs were taken in the fifth day of infection.

The drug Favipiravir was developed by Pittsburgh Labbe Toyama Chemical Company, and was approved to be produced and sold as a new anti-flu drug in Japan in 2014. As an approved drug in the market, its safety and its side effects are relatively clear, thus it is expected to be used to treat "tick disease" soon.

We recommend the following content for you>> http://www.cusabio.com/Recombinant-Protein/Recombinant-Saccharomyces-cerevisiae-strain-ATCC-204508--S288c-Bakers-yeast-Exopolyphosphatase-11106394.html

Halozyme Therapeutics has developed a technology to replace intravenous infusions

A new technology developed by Halozyme Therapeutics, makes injecting biologic drugs under the skin possible rather than with intravenous infusions. Now the American pharmaceutical company, Eli Lilly and Company, is licensing the technology from the company.

Halozyme develops synthetic enzymes on a technology platform which is called Enhanze that adapts the enzyme hyaluronidase. This enzyme acts by degrading hyaluronan, a naturally occurring gel-like substance in skin and cartilage, and also in tumor cells. When formulated for drug delivery, hyaluronidase can help biologics and small-molecule drugs spread quickly in the body under the condition of injecting under the skin.

Halozyme points out that hyaluronidase can also be set to operate under certain conditions, such as when patients show specific physical traits, or when it is necessary to minimize the side effects. The degradation of hyaluronan is temporary, which allows restoration of the degraded cell matrices, according to the company.

Besides, Halozyme is also developing a cancer drug code-named PEGPH20 designed to break up solid-tumor micro-environments protected by high levels of hyaluronan. PEGPH20 is applied in early and medium stage of clinical trials as a treatment for gastric, pancreatic, and non-small cell lung cancer.

The deal between Eli Lilly and Company and Halozyme could bring the latter biotechnology company about $825 million.

Cusabio is a company specialized in production of high quality products for gene, protein, antibody, ELISA kit, raw material for production of diagnostic kit, drug residues, food safety small molecules & other small molecules. Feel free to contact Cusabio if you need. Here is its website: www.cusabio.com